Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
87
NMPA:65
EMA:11
SFDA:8
+1 more agencies
Drug Approvals
Recombinant Follitropin Beta Injection
- Product Name
- 普丽康
- Approval Number
- 国药准字SJ20150066
- Approval Date
- Aug 21, 2024
NMPA
Recombinant Follitropin Beta Injection
- Product Name
- 普丽康
- Approval Number
- 国药准字SJ20150065
- Approval Date
- Aug 21, 2024
NMPA
Mirtazapine Orally Disintegrating Tablets
- Product Name
- 米氮平口腔崩解片
- Approval Number
- 国药准字HJ20160688
- Approval Date
- Dec 18, 2023
NMPA
Mirtazapine Orally Disintegrating Tablets
- Product Name
- 米氮平口腔崩解片
- Approval Number
- 国药准字HJ20160677
- Approval Date
- Dec 18, 2023
NMPA
Mirtazapine Orally Disintegrating Tablets
- Product Name
- 米氮平口腔崩解片
- Approval Number
- 国药准字HJ20160676
- Approval Date
- Dec 18, 2023
NMPA
Ezetimibe and Atorvastatin Calcium Tablets（Ⅱ）
- Product Name
- 依折麦布阿托伐他汀钙片(Ⅱ)
- Approval Number
- 国药准字HJ20230110
- Approval Date
- Sep 12, 2023
NMPA
Ezetimibe and Atorvastatin Calcium Tablets（Ⅰ）
- Product Name
- 依折麦布阿托伐他汀钙片(Ⅰ)
- Approval Number
- 国药准字HJ20230109
- Approval Date
- Sep 12, 2023
NMPA
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
No trials found
News
Shanghai Henlius Biotech Receives FDA Approval for Two Denosumab Biosimilars for Osteoporosis Treatment
Shanghai Henlius Biotech has received FDA approval for two denosumab biosimilars, BILDYOS and BILPREVDA, marking the company's sixth overseas product approval.